1. Introduction {#sec1}
===============

Aluminum (Al) toxicity to bone has been the subject of several reviews, though none recent. The majority of the work was performed in the 1970s through the 1990s and involved either Al contamination of fluid used in hemodialysis or peritoneal dialysis secondary to chronic renal disease or Al contamination of fluids used for the intravenous nutrition of patients with intestinal disease or premature infants who could not tolerate enteral feeds. In both settings it is notable that Al contaminated fluids that were administered by a parenteral route, not through the gastrointestinal tract.

To understand this setting a bit better we will first discuss Al the element in nature and then discuss its kinetics as it relates to handling by the body. Following that we will discuss the manifestations of Al toxicity and the therapeutic options to manage it.

Al is the third most abundant element in the earth\'s crust and is ubiquitous in nature \[[@bib1]\]. There is no known physiological requirement for Al by the body, but it has been known to interact with iron, especially in its affinity for the chelating agent deferoxamine \[[@bib2],[@bib3]\] and in the use of the aurin tricarboxylic acid stain to identify either Al or elemental iron in bone histology \[[@bib4]\]. In addition, 95% of Al circulates in the blood bound to transferrin \[[@bib2],[@bib5]\]. Al may also interact with calcium and has a strong affinity for phosphate \[[@bib6]\].

2. How do we measure Al in fluids and in tissue? {#sec2}
================================================

Al in blood, urine, and tissue is still measured by electrothermal atomic absorption spectroscopy with a Zeeman background correction \[[@bib7],[@bib8]\]. A machine with a Zeeman correction applies a magnetic field to the atomic emissions from specific elements more clearly separating background from substance emissions.

Normal values for human plasma, urine and tissues were published by LeGendre and Alfrey \[[@bib9]\]. The analyses are not widely available or often performed and this makes for scarce data on the subject. Specimens once obtained are dried and ashed prior to analysis \[[@bib7],[@bib8]\].

3. Al handling by the body {#sec3}
==========================

Al can be ingested in any number of foods or medications. Intestinal absorption is very low, estimated at 0.005% \[[@bib10]\] of intake. Al injected subcutaneously does not enter into the circulation but instead accumulates within the dermal layers \[[@bib11]\]. Thus, the intestinal mucosa as well as the skin serve as barriers to Al entry into the blood. What little Al is absorbed is excreted by the kidney, although only about 5% of Al in the circulation is ultrafilterable \[[@bib5]\]. Al ingested orally, for example in antacids or in infant formula, will not accumulate in the body as long as renal function is intact. If the kidney cannot excrete Al, it will accumulate in the body, resulting in manifestations of Al toxicity in chronic renal disease. However, impaired renal function is not required to produce Al toxicity. Bypassing the natural barriers to Al entry into the body, for example, by providing nutrition to a patient by an intravenous route, known as total parenteral nutrition (TPN), Al can still accumulate in the body, attributable to the 95% binding of Al to circulating transferrin. The consequences of the circulation of bound Al are its establishment of equilibrium between the blood and various tissues. Among the tissues in which Al can build up are the bone, liver, spleen, parathyroid glands, and kidney. While little is known of the consequences of Al accumulation in the spleen, a great deal has been learned about the consequences of Al accumulation in bone and parathyroid glands, and some information is available about the effects of Al in liver and kidney ([Fig. 1](#fig1){ref-type="fig"}).Fig. 1Illustration of the various toxic roles of aluminum (Al) in different body organs. PTH, parathyroid hormone.Fig. 1

4. Al accumulation in bone {#sec4}
==========================

Al has been demonstrated in the bones of patients with chronic renal disease undergoing either hemodialysis \[[@bib12]\] or peritoneal dialysis \[[@bib12]\]. It can also accumulate in bone with impaired renal function just by the oral ingestion of Al-containing antacids \[[@bib13]\]. Al also accumulates in the bones of patients receiving long-term treatment with TPN to manage an intestinal disorder that impairs the patient\'s ability to feed enterally \[[@bib14]\]. The upper limits of normal Al content in bone is below 10 μg/g dry weight \[[@bib5],[@bib14]\]. Al content of bone in either renal disease or TPN treatment has reached over 100 μg/g dry weight, although the amount in bone samples of premature infants obtained at autopsy have been somewhat lower \[[@bib15]\]. In either condition Al accumulates at the mineralization front of the bone surface, where osteoblasts have just laid down new type I collagen. Instead of the accumulation of calcium at that spot, a phenomenon that occurs normally, Al preferentially occupies the unmineralized type I collagen, impairing calcification and resulting in osteomalacia. In addition to bone, Al is also taken up by the parathyroid glands \[[@bib16]\] and impairs parathyroid hormone (PTH) secretion \[[@bib16]\]. Whether Al serves to up-regulate the parathyroid calcium-sensing receptor (CaSR) is unclear. No effect of Al on the CaSR was discernible in rat studies \[[@bib17]\]. However, the end result was still a functional hypoparathyroidism \[[@bib16]\] with consequent hypercalciuria \[[@bib5],[@bib14],[@bib15]\]. The end result of these changes is Al displacement of calcium on the bone surface, leading to osteomalacia, hypercalcemia, and hypercalciuria. The apparent contradiction of the coexistence of hypoparathyroidism and hypercalcemia can be explained in parenteral nutrition patients by the constant infusion of calcium-containing solutions while the Al is blocking skeletal uptake of the infused calcium. This leads to an iatrogenic hypercalcemia, which is partially ameliorated by the hypercalciuria associated with the functional hypoparathyroidism. Moreover, the mild hypercalcemia may also contribute to the secondary suppression of PTH secretion. This is the scenario in patients receiving Al-contaminated parenteral nutrition solutions. In patients who suffer from chronic renal disease, inability to excrete phosphate leads to secondary and sometimes tertiary hyperparathyroidism. Thus Al accumulation in the parathyroids leads to a partial amelioration of the secondary hyperparathyroidism rather than to frank hypoparathyroidism \[[@bib17]\]. A potential consequence of this Al displacement of calcium at the bone surface is the occurrence of hungry bone syndrome. This phenomenon occurs when Al is chelated out of bone by use of deferoxamine \[[@bib3]\]. When the Al is freed from the bone by the chelating agent the bone takes up excessive calcium from the circulation leaving the patient with hypocalcemia and an inappropriately low serum concentration of PTH \[[@bib3]\]. This situation is analogous to the hungry bone syndrome that occurs with severe secondary hyperparathyroidism and partial parathyroidectomy which occurs with chronic renal disease. Once the PTH stimulus to bone resorption has been removed by surgery the bone, which had been releasing calcium in response to the hyperparathyroidism sucks the calcium back into the bone from the blood at least temporarily overriding the effect of circulating PTH.

Another result of the Al accumulation in bone and parathyroid is the inhibition of the renal enzyme 25 hydroxyvitamin D-1 alpha hydroxylase (25(OH)D-1-alpha hydroxylase), which converts 25(OH)D to 1 alpha, 25 dihydroxyvitamin D \[[@bib18]\]. Whether it is the relatively low PTH that causes the reduction in conversion of 25(OH)D to its metabolically active form \[[@bib19]\], the renal accumulation of Al that poisons this enzymatic conversion as lead accumulation similarly does, or, especially in the case of chronic renal disease, the accumulation of fibroblast growth factor 23, which suppresses the enzymatic conversion of 25(OH)D to 1,25(OH)~2~D \[[@bib20]\] is presently unclear. One or more of these factors may be involved.

With regard to physical manifestations of Al accumulation in bone, severe bone pain has been manifested in patients with dialysis osteomalacia \[[@bib21]\] as well as in those with TPN-associated osteomalacia \[[@bib22],[@bib23]\]. When Al is removed from the parenterally administered solutions, either dialysis or parenteral nutrition solutions, bone pain resolves, PTH and 1,25-dihydroxyvitamin D concentrations return to normal in the blood \[[@bib23]\]. Exactly what is responsible for the bone pain is unknown, but it is linked in manifestation to the abnormalities in calcium metabolism presented here.

Al toxicity is also associated with anemia \[[@bib24],[@bib25]\], and Al has been identified in macrophages of the bone marrow and may affect the erythrocyte cell line. It is thought to interfere with heme synthesis, possibly by preventing iron incorporation, or it may interfere with the erythrocyte enzyme delta amino levulinic acid dehydratase, the last step in heme synthesis. Al-induced anemia is not necessarily common but may be associated with the generalized uptake of Al by bone and marrow and has only been observed in patients with chronic renal disease, not in those receiving TPN.

5. Al uptake by liver {#sec5}
=====================

Al is also taken up by the liver. This has been documented in patients receiving long-term TPN treatment \[[@bib5]\]. The amount of Al taken up by the liver on a dry weight basis seems to be less than what has been measured in bone \[[@bib5]\]. However, the manifestations of Al toxicity in liver have still been described. They are accumulation of bile acids in serum in rats \[[@bib26]\] and piglets \[[@bib27]\], a change in predominance of amino acids conjugating the bile acids from glycine to taurine \[[@bib28]\] increased transferrin excretion in bile \[[@bib29]\], and, in rats given parenteral Al, reduction of certain cytochrome P450 isoenzymes, NADPH cytochrome c reductase, and a fourfold increase in glucuronyl transferase activity, indicating increased conjugating activity \[[@bib30]\]. Al appears to be preferentially taken up by hepatocyte lysosomes by use of X-ray microanalysis \[[@bib27]\]. Also, in this same study there was a small but significant decrease in serum 25(OH)D, suggesting that liver 25-hydroxylation of the vitamin might also be affected by Al \[[@bib27]\]. The implications of these changes for bone, although the precise pathogenesis of these manifestations is not known, could include a reduction in intestinal calcium and/or vitamin D absorption as well as alteration of drug metabolism by means of changes in cytochrome P450 isoenzymes.

6. Sources of Al contamination {#sec6}
==============================

In chronic renal disease, the documented sources of Al contamination have been the water in the fluid used in hemodialysis \[[@bib12]\] and peritoneal dialysis \[[@bib12]\] as well as oral Al-containing phosphate binders \[[@bib6]\]. In patients receiving TPN, the contaminating sources were not as obvious. Our initial investigations revealed that casein hydrolysate, used as the protein source at the time, was the principal source of Al \[[@bib14]\]. When an essential amino acid solution was substituted for the casein hydrolysate in adult TPN patients suffering from Al toxicity bone pain resolved, PTH and 1,25-dihydroxyvitamin D concentrations in serum rose to normal \[[@bib23]\].

However, that was not the end of the problem. Studies in premature infants, whose renal function is developmentally reduced, revealed that Al in smaller quantities still contaminating TPN solutions were capable of contributing to the incidence of a rachitic like presentation seen in these patients \[[@bib15]\]. The remaining mystery was the source of the Al contamination.

Detailed analysis of the TPN solution components and intravenously administered medications revealed Al contamination of many of the components. A full list, when last determined by our group, is given in [Table 1](#tbl1){ref-type="table"} below \[[@bib15],[@bib31]\], but the main sources were calcium and phosphate salts, albumin and heparin. On careful examination of the contaminated solutions shown in [Table 1](#tbl1){ref-type="table"} the wide variability of Al content is evidence supporting the lack of quality control during the manufacturing process.Table 1Aluminum content of common components of intravenous nutrition solutions.Table 1SolutionConcentrationAluminum content (μg/L)No. of lots testedSalt Calcium gluconate10%5056 ± 3355 Sodium phosphate3000 mmol/L59771 Potassium phosphate3000 mmol/L16,598 ± 18013Serum Albumin25%1822 ± 25034 Heparin1000 units/mL684 ± 7613 Heparin5000 units/mL3591 Heparin10,000 units/mL468 Lipid emulsion1951 Dextrose5%72 ± 12 Sodium chloride4000 mmol/L6 ± 43 Potassium chloride3000 mmol/L61[^1][^2]

7. How could this happen? {#sec7}
=========================

As mentioned at the beginning of this piece, there is no known nutritional requirement for Al, so how did this element end up in TPN solutions, or dialysis fluid for that matter? In the case of dialysis fluid, Al contaminated the water used in dialysis. This problem is now corrected. However, the problem of Al contamination of a variety of salts and other medications is still with us. The U.S. Food and Drug Administration (FDA) has identified that in the case of albumin, a product of human blood, with a normal Al content of less than 10 μg/L, it is the purification process, including the use of glass columns that produces the contamination \[[@bib32]\]. Glass, which contains silicates, also contains Al, and in the purification process the Al is leached from the glass into the product, which has been reported to contain as much as 5 times the Al content of normal serum \[[@bib15],[@bib31]\]. In the case of the calcium and phosphate salts, the problem is a bit more complex.

In 1985, one of my colleagues (Ravi Pottathil, PhD, City of Hope National Medical Center, Duarte CA) showed me a copy of the *Merck Manual*, which lists chemical reagents and their degree of purity. He noted that several designated as ultrapure still contained small amounts of contaminants, such as lead. However, the designation ultrapure was reserved for those reagents that contained contaminants \<1 part per million (ppm). When communicating with the quality control officers of the companies that manufactured these reagents 2 things became clear. The first was that the method for measuring Al was complicated and expensive and was not performed routinely in any industrial setting. Therefore, Al was not listed as a contaminant in any of the reagents in the *Merck Manual.* The second realization was that no one thought that biological effects, especially toxic effects, could be present in quantities less than 1 ppm (1 mg/L). What was clear from our work and from the work of others, however, is that Al exerted biological effects in the parts per billion (ppb) range, in other words, in micrograms/L. Thus, the likely explanation for the contamination of the calcium and phosphate salts with Al is that Al was never measured in the raw material used to make the hospital-grade salts and was not thought to cause toxicity.

The FDA has now partially addressed the problem by publishing a rule regarding the allowable Al content of components of TPN solutions. The amounts of Al at expiry of the solution components must be measured by methods reviewed and acceptable to FDA and must be placed on the label of the solution component along with a boxed warning about the toxicity of Al \[[@bib33]\]. While this rule raises awareness of the problem, in practical terms, it is not clear that there is a uniform way to address this problem. Poole et al. \[[@bib34]\] have demonstrated that while the rule can reduce the amount of Al delivered to preterm infants by selecting the TPN solution components lowest in Al, the FDA designated 'safe' limit of 5 μg/kg/day cannot be met. This 'safe' limit was calculated from the limited published data indicating which types of TPN solutions did not produce Al toxicity. There have to date been no Al dose-response studies to provide a more reliable threshold of toxicity. Currently, the only therapeutic option in managing the Al load received is that advocated by Poole et al. \[[@bib34]\] and implied by the current FDA rule.

While this problem has at least been formally addressed in the United States and in parts of Europe, the degree to which Al contamination and toxicity is a problem in Asia and elsewhere in the world has not been ascertained, especially among patients with renal disease requiring dialysis and premature infants and others requiring TPN.
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[^1]: Values are presented as mean ± standard deviation.

[^2]: Data derived from Sedman et al. N Engl J Med 1985; 312:1337-43 \[[@bib15]\].
